Arxo Findings Register · Arxo Law

ARXO-2026-0321 · Reported

PEG 3350 and electrolytes for oral solution: 7.2 and 2.1 give different instructions for one patient

7.2 reads “Administer oral medications within one hour before the start of administration of GoLYTELY”. 2.1 reads “Do not take oral medications within 1 hour before the start or during administration”. Example: A tablet taken 30 minutes before the opening dose follows 7.2 and breaks 2.1, Highlights and 17. The same text is in 9 labels from 8 labelers in the DailyMed release of 29 October 2026.

Consequence

Potential effect on a prescribing decision: medium. Arxo does not say which instruction is correct and gives no dose.

Jurisdiction
United States — federal
Act
PEG 3350 and electrolytes for oral solution prescribing information (SPL set ID 7609ecf7-0ce0-4fbb-9c27-30987f689575)
Place
7.2 and 2.1
Record
Discrepancy
Class
Text of the act
Where it arose
The text of the act
Arxo's conclusion
Confirmed
Official text
Unchanged at last check
Last checked
2026-10-31

Evidence

Reproduced by execution. Quotations are verbatim from the official material; translations are ours and marked.

Administer oral medications within one hour before the start of administration of GoLYTELY
Official publication · Prescribing information, Azurity Pharmaceuticals, Inc., SPL set ID 7609ecf7-0ce0-4fbb-9c27-30987f689575, version 1 (DailyMed) · 7.2 · version 1 · retrieved 2026-10-29 · SHA-256 159a2be285e0c1940159e36bbcb624cb1e0d66ecbbe0f85e537b56fa6de29dcc · copy
Do not take oral medications within 1 hour before the start or during administration
Official publication · Prescribing information, Azurity Pharmaceuticals, Inc., SPL set ID 7609ecf7-0ce0-4fbb-9c27-30987f689575, version 1 (DailyMed) · 2.1 · version 1 · retrieved 2026-10-29 · SHA-256 159a2be285e0c1940159e36bbcb624cb1e0d66ecbbe0f85e537b56fa6de29dcc · copy

How to check it without Arxo's tools

  1. Open Prescribing information, Azurity Pharmaceuticals, Inc., SPL set ID 7609ecf7-0ce0-4fbb-9c27-30987f689575, version 1 (DailyMed) and find 7.2; 2.1. Compare the text with the quotation above. A copy is kept in this register: 159a2be285e0c194-7609ecf7-0ce0-4fbb-9c27-30987f689575-v1.xml (SHA-256 159a2be285e0c1940159e36bbcb624cb1e0d66ecbbe0f85e537b56fa6de29dcc, copy of the official file).
  2. The finding holds if the quoted passages read as shown and the comparison gives the result stated at the top of this page. If it does not, write to us with the record ID.

How this finding was made

AI agents read the labels, compared their parts and, where marked, ran the example patient through executable rules; an AI agent then read each place in full, with tables and footnotes, and confirmed it. No clinician has assessed these places. A person at Arxo approved publication (2026-10-31).

Responsible institutions

Reported to

DateInstitutionChannelReference
2026-10-31Azurity Pharmaceuticals, Inc.e-mail
2026-10-31U.S. Food and Drug Administration, Center for Drug Evaluation and Researche-mail

Responses

No response recorded.

History

  1. 2026-10-31Confirmed by Arxo
  2. 2026-10-31Reported to Azurity Pharmaceuticals, Inc. (e-mail)
  3. 2026-10-31Reported to U.S. Food and Drug Administration, Center for Drug Evaluation and Research (e-mail)

Cite this record

Arxo Law, Arxo Findings Register, ARXO-2026-0321, https://arxo.io/findings/ARXO-2026-0321/ (status as of 2026-10-31). Data: ARXO-2026-0321.json.